TrialAmerican journal of hematology2015

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Robert Z Orlowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.